Cagrilintide: What It Is and How It's Used in the Philippines

Quick read: Cagrilintide is an amylin analog that slows gastric emptying and reduces appetite. Often combined with semaglutide (CagriSema), it's dosed at 0.16-2.4mg weekly. In PH, it's an emerging compound with limited community data. CagriSema trials show 15-20% weight loss, similar to retatrutide.

What it is

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin that slows gastric emptying and reduces appetite. It's being developed by Novo Nordisk, often in combination with semaglutide as "CagriSema."

The mechanism: Amylin slows gastric emptying (you feel full longer) and acts on the brain to reduce appetite. Combined with semaglutide (GLP-1), it creates dual appetite suppression.

Research shows CagriSema produces 15-20% weight loss over 68 weeks, similar to retatrutide but with different mechanisms.

In the PH peptide community, cagrilintide is rarely used standalone. Most interest is in CagriSema combinations, though availability is limited.

What it's used for

Primary use: Weight loss (combined with semaglutide). CagriSema for compound appetite suppression and fat loss.

Realistic expectations: Limited community data. Trials suggest 15-20% weight loss over 68 weeks.

Typical protocols

CagriSema protocol (from trials):

• Cagrilintide: 0.16-2.4mg weekly
• Semaglutide: 1.0-2.4mg weekly
• Duration: 6-12 months

Standalone cagrilintide protocols are not well-established.

What users typically report

Limited community data. CagriSema users report strong appetite suppression similar to retatrutide.

Common side effects

Nausea (40-50%): Similar to GLP-1 agonists.

GI upset: Constipation, bloating, reflux.

Side effect management

Same as GLP-1 agonists: eat smaller meals, avoid high-fat foods, manage with famotidine if needed.

Who this compound is for

Emerging compound for users interested in combination therapy beyond retatrutide/tirzepatide.

Who this compound is NOT for

Pregnancy/breastfeeding.

People with gastroparesis.

PH-specific considerations

Emerging compound, limited PH community data yet. Availability is low. Most users stick to retatrutide, tirzepatide, or semaglutide.

Common stacks

Typically combined with semaglutide as CagriSema.

Things to watch

Same as GLP-1 agonists: fasting glucose, HbA1c, lipids.

Coming off / cycling

Same as GLP-1 agonists: appetite returns after stopping.

Related compounds

• Semaglutide — Often combined with cagrilintide
• Retatrutide — Alternative triple agonist
• Tirzepatide — Dual GLP-1/GIP agonist

Sources

• Lau 2021 — Cagrilintide amylin analog mechanisms
• Enebo 2021 — CagriSema trial data

Last updated: 2026-05-20. This page is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.